The management of Hypertrophic Cardiomyopathy (HCM) has evolved significantly, shifting from purely symptomatic relief to a comprehensive strategy focused on sudden cardiac death (SCD) prevention and specialized interventions for outflow tract obstruction.
Comprehensive Management Strategy
Medical Management (First-Line)
The primary goal is to improve diastolic filling and reduce the pressure gradient across the Left Ventricular Outflow Tract (LVOT).
- Beta-Blockers: The cornerstone of therapy (e.g., Metoprolol, Atenolol). They decrease heart rate, increase diastolic filling time, and reduce ionotropic response.
- Calcium Channel Blockers: Non-dihydropyridines like Verapamil are used if beta-blockers are poorly tolerated or ineffective.
- Caution: Avoid in patients with severe resting obstruction or heart failure.
- Disopyramide: An anti-arrhythmic with negative inotropic effects, often added to beta-blockers to further reduce LVOT gradients.
- Mavacamten: A newer, first-in-class cardiac myosin inhibitor specifically approved for symptomatic obstructive HCM.
Sudden Cardiac Death (SCD) Risk Stratification
All patients must be assessed for an Implantable Cardioverter-Defibrillator (ICD) based on:
- Prior cardiac arrest or sustained Ventricular Tachycardia (VT).
- Family history of premature HCM-related death.
- Massive left ventricular hypertrophy (wall thickness ≥ 30mm).
- Unexplained syncope.
- Apical aneurysms or low LVEF (< 50%).
Genetic Analysis in HCM
Genetic testing is a Class I recommendation for patients with a clinical diagnosis of HCM. It serves two primary purposes:
- Etiology Clarification: Identifying “HCM mimics” such as Fabry disease, Friedreich’s ataxia, or ATTR amyloidosis, which require entirely different treatment pathways.
- Cascade Screening: Once a pathogenic variant is found in the “proband” (the affected patient), first-degree relatives can be tested.
- Genotype-negative relatives can generally be discharged from regular clinical surveillance.
- Genotype-positive relatives require longitudinal monitoring (ECG/Echo) even if currently asymptomatic.
- Common Genes: Most mutations occur in the cardiac sarcomere, specifically MYH7 (Beta-myosin heavy chain) and MYBPC3 (Myosin-binding protein C).
Alcohol Septal Ablation
ASA is a percutaneous (non-surgical) intervention for patients with obstructive HCM who remain symptomatic despite optimal medical therapy.
The Procedure
- Localization: A tiny amount of absolute ethanol (95-98%) is injected into a specific septal perforator artery.
- Controlled Infarction: The alcohol causes a localized “planned myocardial infarction” of the basal septum.
- Remodeling: The infarcted tissue thins and scars over time, widening the LVOT and reducing the pressure gradient and mitral valve systolic anterior motion (SAM).
ASA vs. Surgical Myectomy
| Feature | Alcohol Septal Ablation (ASA) | Septal Myectomy (Surgery) |
| Invasiveness | Minimally invasive (catheter-based) | Open-heart surgery |
| Recovery | Shorter hospital stay | Longer recovery period |
| Common Risk | Permanent Pacemaker requirement (due to Heart Block) | Less risk of complete heart block |
| Effectiveness | Highly effective; results depend on vascular anatomy | The “Gold Standard” for long-term relief |
ASA is generally preferred for older patients or those with significant comorbidities, whereas Myectomy is often favored for younger patients or those with concomitant mitral valve disease.